AI
AXSM icon

Atria Investments’s Axsome Therapeutics AXSM Stock Holding History

Atria Investments’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$235K Sell
961
-414
-30% -$89.8K ﹤0.01% 1984
2026
Q1 		$232K Sell
1,375
-288
-17% -$49.7K ﹤0.01% 1899
2025
Q4 		$304K Sell
1,663
-106
-6% -$14.8K ﹤0.01% 1730
2025
Q3 		$215K Buy
+1,769
New +$199K ﹤0.01% 1907

Other funds holding AXSM

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Atria Investments's AXSM Position: Q2 2026 in Review

Atria Investments reduced its Axsome Therapeutics (AXSM) stake by 30% in Q2 2026, selling an estimated $89.8K and leaving 961 shares worth $235K. The position accounts for ﹤0.01% of the portfolio, ranked #1984.

Atria Investments first reported a position in AXSM in Q3 2025 and has held it in 4 quarters since. The position peaked at $304K in Q4 2025. 506 funds tracked by Wall St. Rank hold AXSM as of Q2 2026.

  • Atria Investments held 961 shares of Axsome Therapeutics worth $235K as of Q2 2026.
  • Atria Investments sold 414 Axsome Therapeutics shares in Q2 2026, an estimated $89.8K.
  • Axsome Therapeutics made up ﹤0.01% of Atria Investments's portfolio in Q2 2026, its #1984 holding.
  • Atria Investments first reported a position in Axsome Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • Atria Investments's Axsome Therapeutics position peaked at $304K in Q4 2025.
  • 506 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q2 2026.

Based on Atria Investments's 13F filing for Q2 2026, filed 28 Jul 2026.